Congress spares pharmas from going over another cliff—for now

Share this article:
In capital, parties argue generic label freedom
In capital, parties argue generic label freedom

For the drug industry, the big news in the “fiscal cliff” deal is that the next big congressional showdown—one that could have big implications for the healthcare industries—has been kicked down the road a couple months.

As part of the bargain over the so-called “cliff,” the economic reckoning that would have happened as the hefty Bush tax cuts abruptly ended, Congress agreed to put off the “Sequester,” a brutal series of mandatory budget cuts meant to backstop more reasoned budgeting that never happened, by two months. The Sequester would slash $318 million from FDA's 2013 budget of $4.5 billion—a 7% reduction overnight, two months into the year—resulting in layoffs that would dramatically slow down the approvals process and prevent manufacturers from bringing new drugs to market. That could set up a vicious circle by compromising FDA's ability to collect user fees which account for nearly half of its annual budget, further gumming up the works.

While Medicare would be relatively unscathed—cuts to the program are limited to 2% in the Sequester legislation—and Medicaid and CHIP would be spared entirely, other arms of the federal healthcare bureaucracy would be hard hit. CDC would lose $490 million—4.3% of the Centers' $11.2 billion 2013 budget—and NIH would lose $2.5 billion, or just over 8% of its $30.7 billion budget.

The clock on that fiscal train wreck has been reset to March 1.

Elsewhere in the deal that passed the House of Representatives last night, physicians won a one year reprieve for the so-called “doc fix,” which ensures that physicians are fully compensated for Medicare patients, despite a shortfall in funding that would otherwise have given them a 26.5% pay cut on those cases. President Obama had pushed a permanent fix for the shortfall as part of a bigger earlier deal that was scuttled when it came up short of necessary support in the House. Hospitals got stuck with the bill for the patch—the legislation cuts their Medicare and Medicaid reimbursements.

“While fixing the physician payment formula is essential, it should not be done by jeopardizing hospitals' ability to care for seniors and their communities,” said American Hospital Association chief Rich Umbdenstock in a statement.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...